



05-01-06

Attorney's Docket No.: 14875-154US1 / C1-A0304P-US

1PW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Taro Miyazaki et al.

Art Unit : Unknown

Serial No. : 10/560,098

Examiner : Unknown

Filed : December 9, 2005

Title : METHODS FOR PRODUCING ANTIBODIES

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Copies of the references are enclosed, including an English translation of reference AH. A translation of reference AI is not included, since it is a family application of reference AD. Also enclosed are a copy of the International Search Report and an English translation of the International Preliminary Report on Patentability.

Applicants wish to bring to the Examiner's attention co-pending and co-owned non-provisional applications serial numbers 10/510,971 (Attorney Docket No. 14875-134US1) and 10/542,839 (Attorney Docket No. 14875-148US1), which have overlapping inventorship with the above-referenced application and concern related subject matter. Applicants assume that the Examiner has ongoing access to the files of these related applications and can obtain copies of prosecution documents from the files if at any point in the future he/she considers them potentially relevant to issues in the present application. Applicants will supply copies of such documents from the related application's files, should the Examiner request them.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EV366532507US

Date of Deposit

4/28/2006

Applicant : Taro Miyazaki et al.
Serial No. : 10/560,098
Filed : December 9, 2005
Page : 2 of 2


Attorney's Docket No.: 14875-154US1 / C1-A0304P-
US

This statement is being filed before the receipt of a first Office Action on the merits.
Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney
Docket No. 14875-154US1.

Respectfully submitted,

Date: _____


4/28/2006


Janis E. Fraser, Ph.D., J.D.
Reg. No. 34,819

Janice L. Kugler
Reg. No. 50,429

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

21312153.doc



Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-154US1	Application No. 10/560,098
	Applicant Taro Miyazaki et al.		
	Filing Date December 9, 2005		Group Art Unit

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AC	WO 96/34892	11/07/1996	WIPO				
	AD	WO 98/50431	11/12/1998	WIPO				
	AE	WO 00/44788	08/03/2000	WIPO				
	AF	WO 01/44282	06/21/2001	WIPO				
	AG	WO 01/70775	09/27/2001	WIPO				
	AH	WO 03/087163	10/23/2003	WIPO			X	
	AI	2001-523971	11/27/2001	JAPAN				X

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AJ	Carter, "Bispecific human IgG by design", J. Immunol. Methods, 248:7-15 (2001)
	AK	Peipp et al., "Bispecific antibodies targeting cancer cells", Biochem. Soc. Trans., 30:507-11 (2002)
	AL	Ridgway et al., "'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization", Protein Engineering 9:617-621 (1996)
	AM	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene", J. Exp. Med., 175:217-225 (1992)
	AN	Skerra, "Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in <i>Escherichia coli</i> ", Gene, 151:131-5 (1994)
	AO	Zuo et al., "An efficient route to the production of an IgG-like bispecific antibody", Protein Engineering 13:361-367 (2000)
	AP	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	